Metropolis Dermatology

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)3 trials
• Psoriasis3 trials
• Obesity2 trials

Phase

• Phase 23 trials
• Phase 32 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company2 trials
• Sun Pharmaceutical Industries Limited2 trials
• Apollo Therapeutics Ltd1 trial
• Incyte Corporation1 trial

Running trials

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

  Contact: Jayda Pham

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Eli Lilly and Company· Source

  Contact: Yen (James) Wang (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

  NCT06588283· Phase 3· Eli Lilly and Company· Source

• Completed

  To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT04684485· Phase 2· Sun Pharmaceutical Industries Limited· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source

• Completed

  To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

  NCT04566666· Phase 2· Sun Pharmaceutical Industries Limited· Source